Payment overview · 2025
General Payments
$173.95
9 reported records · 8 companies
Healthcare provider profile · identity verified
Denise Pine-Mattas, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARSHALL, IL · NPI 1659313989
Verified facts
What the public records show
CMS Open Payments records show Denise Pine-Mattas, MD received $173.95 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.40 | 19.8% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.13 | 17.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.41 | 11.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.98 | 10.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.26 | 10.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.82 | 10.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.24 | 9.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.71 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.95 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $31.13 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
45 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 412 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 236 | 61 |
| Omeprazole | Omeprazole | 172 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 166 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 42 |
| Losartan Potassium | Losartan Potassium | 131 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 124 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 35 |
| Lorazepam | Lorazepam | 121 | 28 |
| Lisinopril | Lisinopril | 112 | 37 |
| Alprazolam | Alprazolam | 111 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 26 |
| Furosemide | Furosemide | 92 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 28 |
| Potassium Chloride | Potassium Chloride | 88 | 24 |
| Alendronate Sodium | Alendronate Sodium | 87 | 23 |
| Allopurinol | Allopurinol | 82 | 19 |
| Montelukast Sodium | Montelukast Sodium | 81 | 19 |
| Lovastatin | Lovastatin | 80 | 20 |
| Buspirone Hcl | Buspirone Hcl | 78 | 17 |
| Sertraline Hcl | Sertraline Hcl | 73 | 18 |
| Metformin Hcl | Metformin Hcl | 71 | 18 |
| Mounjaro | Tirzepatide | 70 | 11 |
| Eliquis | Apixaban | 69 | 11 |
| Cephalexin | Cephalexin | 64 | 40 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 43 |
| Metformin Hcl Er | Metformin Hcl | 59 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 18 |
| Azithromycin | Azithromycin | 56 | 46 |
| Amoxicillin | Amoxicillin | 55 | 46 |
| Atenolol | Atenolol | 55 | 15 |
| Gabapentin | Gabapentin | 55 | 18 |
| Simvastatin | Simvastatin | 55 | 15 |
| Carvedilol | Carvedilol | 53 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 51 | 14 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Ozempic | Semaglutide | 50 | suppressed |
| Meloxicam | Meloxicam | 49 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 15 |
| Ezetimibe | Ezetimibe | 48 | 11 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 32 |
| Tramadol Hcl | Tramadol Hcl | 43 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Famotidine | Famotidine | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Methylprednisolone | Methylprednisolone | 39 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Praluent Pen | Alirocumab | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Constulose | Lactulose | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.95 · 9 records | GlaxoSmithKline, LLC. | AREXVY, Dexcom G6 Transmitter, JARDIANCE, LEQVIO, Ohtuvayre, Ozempic, Qelbree, SHINGRIX, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error